Molecular Tumor Board: 67-year-old male with HER2-positive, PD-L1 positive advanced gastric adenocarcinoma and 70-year-old male with HER2-negative, PD-L1 negative metastatic gastric adenocarcinoma

What is the current and future state of biomarker testing in gastric cancer?

Find out in this molecular tumor board where we present two cases of advanced stage gastric cancer with contrasting molecular features. We reviewed current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. We also discussed best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology.